| |  Online-Ressource |
|---|
| Verfasst von: | Penack, Olaf [VerfasserIn]  |
|---|
| | Dreger, Peter [VerfasserIn] |
|---|
| | Ajib, Salem [VerfasserIn] |
|---|
| | Ayuk, Francis [VerfasserIn] |
|---|
| | Baermann, Ben-Niklas [VerfasserIn] |
|---|
| | Bug, Gesine [VerfasserIn] |
|---|
| | Kriege, Oliver [VerfasserIn] |
|---|
| | Jentzsch, Madlen [VerfasserIn] |
|---|
| | Kobbe, Guido [VerfasserIn] |
|---|
| | Koenecke, Christian [VerfasserIn] |
|---|
| | Lutz, Mathias [VerfasserIn] |
|---|
| | Martin, Sonja [VerfasserIn] |
|---|
| | Schlegel, Paul-Gerhard [VerfasserIn] |
|---|
| | Schroers, Roland [VerfasserIn] |
|---|
| | von Tresckow, Bastian [VerfasserIn] |
|---|
| | Vucinic, Vladan [VerfasserIn] |
|---|
| | Subklewe, Marion [VerfasserIn] |
|---|
| | Bethge, Wolfgang [VerfasserIn] |
|---|
| | Wolff, Daniel [VerfasserIn] |
|---|
| Titel: | Management of patients undergoing CAR-T cell therapy in Germany |
|---|
| Verf.angabe: | Olaf Penack, Peter Dreger, Salem Ajib, Francis Ayuk, Ben-Niklas Baermann, Gesine Bug, Oliver Kriege, Madlen Jentzsch, Guido Kobbe, Christian Koenecke, Mathias Lutz, Sonja Martin, Paul-Gerhard Schlegel, Roland Schroers, Bastian von Tresckow, Vladan Vucinic, Marion Subklewe, Wolfgang Bethge, Daniel Wolff |
|---|
| E-Jahr: | 2024 |
|---|
| Jahr: | March 2024 |
|---|
| Umfang: | 10 S. |
|---|
| Fussnoten: | Online veröffentlicht: 10. Januar 2024 ; Gesehen am 13.09.2024 |
|---|
| Titel Quelle: | Enthalten in: Oncology research and treatment |
|---|
| Ort Quelle: | Basel : Karger, 2014 |
|---|
| Jahr Quelle: | 2024 |
|---|
| Band/Heft Quelle: | 47(2024), 3 vom: März, Seite 65-75 |
|---|
| ISSN Quelle: | 2296-5262 |
|---|
| Abstract: | Introduction: Chimeric antigen receptor positive T cell (CAR-T cell) treatment became standard therapy for relapsed or refractory hematologic malignancies, such as non-Hodgkin’s lymphoma and multiple myeloma. Owing to the rapidly progressing field of CAR-T cell therapy and the lack of generally accepted treatment guidelines, we hypothesized significant differences between centers in the prevention, diagnosis, and management of short- and long-term complications. Methods: To capture the current CAR-T cell management among German centers to determine the medical need and specific areas for future clinical research, the DAG-HSZT (Deutsche Arbeitsgemeinschaft für Hämatopoetische Stammzelltransplantation und Zelluläre Therapie; German Working Group for Hematopoietic Stem Cell Transplantation and Cellular Therapy) performed a survey among 26 German CAR-T cell centers. Results: We received answers from 17 centers (65%). The survey documents the relevance of evidence in the CAR-T cell field with a homogeneity of practice in areas with existing clinical evidence. In contrast, in areas with no - or low quality - clinical evidence, we identified significant variety in management in between the centers: management of cytokine release syndrome, immune effector cell-related neurotoxicity syndrome, IgG substitution, autologous stem cell backups, anti-infective prophylaxis, and vaccinations. Conclusion: The results indicate the urgent need for better harmonization of supportive care in CAR-T cell therapies including clinical research to improve clinical outcome. |
|---|
| DOI: | doi:10.1159/000536201 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1159/000536201 |
|---|
| | DOI: https://doi.org/10.1159/000536201 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| K10plus-PPN: | 190252263X |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Management of patients undergoing CAR-T cell therapy in Germany / Penack, Olaf [VerfasserIn]; March 2024 (Online-Ressource)
